The presence of critical genetic variations in the NOS1 gene in ketamine users could increase the susceptibility of schizophrenic negative symptoms and potentially with more cognitive impairment while being challenged by chronic ketamine usage which could further reduce the functioning of NOS1 by upstream NMDAR blockade. This evidence concerns the gene NOS1 and Cognitive impairment.